

(51) International Patent Classification:
C07D 401/04 (2006.01)(21) International Application Number:
PCT/US2015/066345(22) International Filing Date:
17 December 2015 (17.12.2015)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
62/094,425 19 December 2014 (19.12.2014) US(71) Applicant: ARAGON PHARMACEUTICALS, INC.
[US/US]; 12780 El Camino Real, Suite 301, San Diego,
California 92130 (US).(72) Inventors: HAIM, Cyril Ben; Krommenhof 54, 2340
Beerse (BE). HORVATH, Andras; Smalvoortstraat 46
bus 2, B2300 Turnhout (BE). WEERTS, Johan Erwin
Edmond; Statiestraat 7, 2340 Beerse (BE). ALBANEZE-
WALKER, Jennifer; Frankfurtlaan 1, 2400 Mol (BE).(74) Agents: PLANTZ, Bernard F. et al.; JOHNSON &
JOHNSON, One Johnson & Johnson Plaza, New Brun-
swick, New Jersey 08933 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN COMPOUND



(57) Abstract: Disclosed are processes and intermediates for the preparation of compound (X), which is currently being investigated for the treatment of prostate cancer.

**PROCESSES FOR THE PREPARATION OF A DIARYLTHIOHYDANTOIN
COMPOUND**

5 **CROSS-REFERENCE TO RELATED APPLICATIONS**

This Application claims priority to United States Provisional Patent Application No. 62/094425, filed December 19, 2014, which is hereby incorporated by reference in its entirety.

10

**STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT**

The research and development of the invention described below was not federally sponsored.

15

FIELD OF THE INVENTION


The present invention is directed to the preparation of compound (X) and intermediates in its synthesis. More specifically, the present invention is directed to processes for the preparation of compound (X), disclosed in United States Patent No. 20 8,445,507, issued on May 21, 2013, which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION


Compound (X) of the present invention is currently being investigated for use in 25 the treatment of prostate cancer. The present invention describes processes and intermediates for the preparation of such compound.

SUMMARY OF THE INVENTION


The present invention is directed to a process for the preparation of compound (X)




Comprising, consisting of, and/or consisting essentially of



- 5 reacting compound (V) with cyclobutanone in the presence of sodium cyanide; in a solvent such as acetic acid, or a solvent system comprised, consisting, or consisting essentially of an alcoholic solvent and a protic acid; at a temperature of about 0 °C to about 20 °C; to yield the corresponding compound (VI);




- 10 reacting compound (IV) and compound (VI) in the presence of a thiocarbonylating agent; in an organic solvent; at a temperature of about 0 °C to about 100 °C; to yield the corresponding compound (VII);




- 15 converting compound (VII) to compound (X), discussed in further detail below.

In one embodiment, compound (VII) is converted to compound (X) via its corresponding carboxylic acid (1c), as shown in scheme (1c), by




(i) reacting compound (VII) with an organomagnesium halide; in the presence or
 5 absence of a lithium halide; followed by the addition of carbon dioxide gas; in an aprotic organic solvent; at a temperature of about 0 °C; to yield the corresponding carboxylic acid compound (1c); or,

(ii) reacting compound (VII) under a carbon monoxide atmosphere; in the presence
 of a palladium catalyst; in the presence of one or more phosphorus ligands; in the presence
 10 of an organic base; in the presence of water; in an organic solvent; at a temperature of about 0 °C to about 100 °C; to yield the corresponding compound (1c); then,




reacting compound (1c) with a coupling agent; in an aprotic or protic solvent; at
 about room temperature; followed by the addition of methylamine; to yield the
 15 corresponding compound (X).

In another embodiment, compound (VII) is converted to compound (X) via its corresponding C₁₋₆alkyl ester (1e), as shown in scheme (1e), by




(i) reacting compound (VII) with an organomagnesium halide; in the presence or absence of a lithium halide; in an aprotic organic solvent; at a temperature of about -50 °C to about room temperature; followed by the addition of an C₁₋₆alkyl chloroformate or C₁₋₆alkyl cyanoformate; to yield the corresponding ester of formula (1e); or

(ii) reacting compound (VII) under suitable alkoxy carbonylation conditions; under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; in the presence of a base; in a C₁₋₆alcoholic solvent; at a temperature of about room temperature to about 100 °C; to yield the corresponding compound of formula (1e); then



treating a compound of formula (1e) with methylamine; in a protic or aprotic solvent; at a temperature of about 0 °C to about 60 °C; to yield the corresponding compound (X).

In another embodiment, compound (VII) is converted directly to compound (X), as shown in scheme (1g), by



(i) reacting compound (VII) in the presence of molybdenum hexacarbonyl; optionally in the presence of one or more reagents such as norbornadiene, tetrabutylammonium bromide, or a base selected from triethylamine or DABCO; in an

organic solvent; followed by the addition of methylamine; at a temperature of about 60 °C to about 140 °C; to yield the corresponding compound (X); or,

- (ii) reacting compound (VII) under suitable aminocarbonylation conditions; under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; in the presence of a base; in the presence of methylamine; in an organic solvent; at a temperature of about room temperature to about 100 °C; to yield the corresponding compound (X).

DETAILED DESCRIPTION OF THE INVENTION

The term “alkyl” whether used alone or as part of a substituent group, refers to straight and branched carbon chains having 1 to 8 carbon atoms. Therefore, designated numbers of carbon atoms (e.g., C₁₋₈) refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyl-containing substituent. In substituent groups with multiple alkyl groups such as, (C₁₋₆alkyl)₂amino-, the C₁₋₆alkyl groups of the dialkylamino may be the same or different.

The term “alkoxy” refers to an -O-alkyl group, wherein the term “alkyl” is as defined above.

The term “cycloalkyl” refers to a saturated or partially saturated, monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

The term “aryl” refers to an unsaturated, aromatic monocyclic or bicyclic ring of 6 to 10 carbon members. Examples of aryl rings include phenyl and naphthalenyl.

The term “halogen”, “halide”, or “halo” refers to fluorine, chlorine, bromine and iodine atoms.

The term “carboxy” refers to the group -C(=O)OH.


The term “formyl” refers to the group -C(=O)H.

The term “oxo” or “oxido” refers to the group (=O).

Whenever the term “alkyl” or “aryl” or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including

those limitations given above for “alkyl” and “aryl.” Designated numbers of carbon atoms (e.g., C₁-C₆) refer independently to the number of carbon atoms in an alkyl moiety, an aryl moiety, or in the alkyl portion of a larger substituent in which alkyl appears as its prefix root. For alkyl and alkoxy substituents, the designated number of carbon atoms includes
 5 all of the independent members included within a given range specified. For example C₁₋₆ alkyl would include methyl, ethyl, propyl, butyl, pentyl and hexyl individually as well as sub-combinations thereof (e.g., C₁₋₂, C₁₋₃, C₁₋₄, C₁₋₅, C₂₋₆, C₃₋₆, C₄₋₆, C₅₋₆, C₂₋₅, etc.).

In general, under standard nomenclature rules used throughout this disclosure, the terminal portion of the designated side chain is described first followed by the adjacent
 10 functionality toward the point of attachment. Thus, for example, a “C₁-C₆ alkylcarbonyl” substituent refers to a group of the formula:



The term “room temperature” or “ambient temperature”, as used herein refers to a temperature in the range of from about 18 °C to about 22 °C.

15 Abbreviations used in the instant specification, particularly the schemes and examples, are as follows:

Abbreviations


aq	aqueous
BA	[1,1'-biphenyl]-2-amine
Boc	<i>tert</i> -butoxycarbonyl
CDI	1,1'-carbonyldiimidazole
CPME	cyclopentyl methylether
Cy	cyclohexyl
DABCO	1,4-diazabicyclo[2.2.2]octane
DCM	dichloromethane
DIEA or DIPEA	diisopropylethylamine
DMA	dimethylacetamide

Abbreviations

DMF	dimethylformamide
DMSO	methyl sulfoxide
dppf	1,1'-bis(diphenylphosphino)ferrocene
h	hour(s)
HCl	hydrochloric acid
HPLC	high performance liquid chromatography
Me	methyl
MeCN	acetonitrile
MeOH	methyl alcohol
mg	milligram
MTBE	methyl <i>tert</i> -butylether
NMP	<i>N</i> -methyl-2-pyrrolidone
PdCl ₂ (dppf) CH ₂ Cl ₂	1,1'-bis(diphenylphosphino)ferrocene- palladium(II)dichloride dichloromethane complex)
P(<i>o</i> -tol) ₃	tri(<i>o</i> -tolyl)phosphine
rt	room temperature
THF	tetrahydrofuran
2-MeTHF	2-methyl tetrahydrofuran

General Schemes

The overall scheme for the present invention is illustrated in Scheme A, shown below.

Scheme A

5 In Scheme A, a compound (V) may be reacted with cyclobutanone and at least one molar equivalent of sodium cyanide; in a solvent such as acetic acid, or in a solvent system comprised, consisting, or consisting essentially of of at least one molar equivalent of an acid such as acetic acid or hydrochloric acid and a C₁₋₄alcoholic solvent such as methanol, ethanol, propanol, or butanol; at a temperature of about 0 °C to about 20 °C; to yield the
10 corresponding compound (VI).

In one embodiment, the solvent is acetic acid.

In another embodiment, the solvent system is 90% acetic acid and 10% ethanol.

Compound (IV) may be reacted with a compound of formula (VI) in the presence of a thiocarbonylating agent selected from 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one, 1,1'-thiocarbonyl diimidazole, phenylthionochloroformate, beta-naphthyl thionochloroformate, 1,1'-thiocarbonylbis(pyridin-2(1*H*)-one), *O,O*-di(pyridin-2-yl)carbonothioate, 1,1'-thiocarbonylbis (1*H*-benzotriazole), or thiophosgene; in an organic solvent such as THF, 2-methyl-THF, acetonitrile, DMA, toluene, DMF, NMP, DMSO, or the like; at a temperature of about 0 °C to about 100 °C; to yield the corresponding compound (VII).

In one embodiment, the thiocarbonylating agent is 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one.

In another embodiment, the organic solvent is DMA.

Conversion to Compound (X) via Carboxylic Acid (1c)

(i) Compound (VII) may be converted to compound (X) via its corresponding carboxylic acid, compound (1c), by reacting compound (VII) with an organomagnesium halide selected from C₁₋₈alkylmagnesium halide or C₅₋₇cycloalkylmagnesium halide; in the presence or absence of a lithium halide such as lithium chloride, lithium bromide, or lithium iodide; followed by the addition of carbon dioxide gas; in an aprotic organic solvent selected from THF, 2-MeTHF, MTBE, CPME, or toluene; at a temperature of about 0 °C; to yield the corresponding carboxylic acid compound (1c).

More particularly, the C₁₋₈alkylmagnesium halide is a C₁₋₈alkylmagnesium chloride or C₁₋₈alkylmagnesium bromide, and the C₅₋₇cycloalkylmagnesium halide is a C₅₋₇cycloalkylmagnesium chloride or C₅₋₇cycloalkylmagnesium bromide.

In one embodiment, the C₁₋₈alkylmagnesium halide is selected from isopropylmagnesium chloride, *sec*-butylmagnesium chloride, *n*-pentylmagnesium chloride, hexylmagnesium chloride, ethylmagnesium chloride, ethylmagnesium bromide, *n*-butylmagnesium chloride, or isopropylmagnesium chloride.

In a further embodiment, the C₁₋₈alkylmagnesium halide is *n*-pentylmagnesium chloride; and the aprotic organic solvent is THF.


In a further embodiment, a lithium halide is absent.




In another embodiment, the C₅₋₇cycloalkylmagnesium halide is
 5 cyclohexylmagnesium chloride.


(ii) Alternatively, compound (VII) may be reacted under a carbon monoxide atmosphere, in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; in the presence of water; in a solvent such as methanol, ethanol, or the
 10 like; at a temperature of about 0 °C to about 100 °C; to yield the corresponding compound (1c).

It has been found that a variety of palladium catalysts and phosphorus ligands are suitable for this transformation. In an embodiment, the palladium catalyst is either a pre-formed palladium catalyst or a palladium-ligand catalyst complex that is formed *in situ*.
 15 When the palladium catalyst is a pre-formed palladium catalyst, it is selected from CAT1 to CAT5, shown in Table 1, and may be used for the above-described preparation of compound (1c).

Table 1. Pre-formed Palladium Catalysts

Catalyst No.	Catalyst Name	Structure
CAT1	Pd(OMs)(BA) (P(tBu) ₂ -4- <i>N,N</i> -dimethylaniline))	



Catalyst No.	Catalyst Name	Structure
CAT2	$\text{Pd}(\text{OMs})(\text{BA})$ ($\text{P}(\text{tBu}_2\text{-neopentyl})$)	
CAT3	$\text{Pd}(\text{P}(\text{tBu}_3)_2)$	
CAT4	$[\text{Pd}(\text{OAc})$ $(\text{P}(\text{o-Tol})_3)_2]$	







Catalyst No.	Catalyst Name	Structure
CAT5	$[\text{PdCl}_2(\text{L3})] = \text{PdCl}_2(\text{dppf})$	

In another embodiment, one or more phosphorus ligands selected from L1 to L17, shown in Table 2, may be used in combination with either a pre-formed palladium catalyst (Table 1) or a palladium metal compound (Table 3), for the preparation of compound (1c).



5

Table 2. Phosphorus Ligands

Ligand No.	Structure
L1	
L2	



Ligand No.	Structure
L3	
L4	
L5	
L6	
L7	
L8	

Ligand No.	Structure
L9	
L10	
L11	
L12	
L13	
L14	
L15	

Ligand No.	Structure
L16	
L17	

In another embodiment, a palladium metal compound selected from M1 to M2, shown in Table 3 may be used.

Table 3. Palladium Metal Compounds

Metal No.	Metal Cpd Name	Structure
M1	palladium acetate	
M2	$[\text{Pd}(\text{OMs})(\text{BA})]_2$	

5

In an embodiment, the palladium catalyst is comprised, consisting, or consisting essentially of the phosphorus ligand dppf (L1, Table 2) and the palladium metal compound palladium acetate (M1, Table 3).

Compound (1c) may then be treated with a coupling agent such as CDI; in an
 10 aprotic or protic solvent such as THF, toluene, or the like; at about room temperature; followed by the addition of methylamine; to yield the corresponding compound (X).

In one embodiment, methylamine is added as a solution in a protic or aprotic solvent. In a further embodiment, methylamine is added as a THF solution.

In another embodiment, methylamine is added in its gaseous state.

In yet another embodiment, methylamine is added as its methyl ammonium salt.

5

Conversion to Compound (X) via Ester (1e)

(i) Compound (VII) may also be converted to compound (X) via its corresponding C₁₋₆alkyl ester (1e), by reacting compound (VII) with an organomagnesium halide selected from a C₁₋₈alkylmagnesium halide or a C₅₋₇cycloalkylmagnesium halide; in the presence or
10 absence of a lithium halide such as lithium chloride, lithium bromide, or lithium iodide; in an aprotic organic solvent selected from THF, 2-MeTHF, toluene, or the like; at a temperature of about -50 °C to about 22 °C; followed by the addition of a C₁₋₆alkyl chloroformate or C₁₋₆alkyl cyanoformate; to yield the corresponding ester of formula (1e).

More particularly, the C₁₋₈alkylmagnesium halide is a C₁₋₈alkylmagnesium chloride
15 or C₁₋₈alkylmagnesium bromide, and the C₅₋₇cycloalkylmagnesium halide is a C₅₋₇cycloalkylmagnesium chloride or C₅₋₇cycloalkylmagnesium bromide.

In one embodiment, the C₁₋₈alkylmagnesium halide is selected from isopropylmagnesium chloride, *sec*-butylmagnesium chloride, cyclohexylmagnesium chloride, *n*-pentylmagnesium chloride, hexylmagnesium chloride, ethylmagnesium
20 chloride, ethylmagnesium bromide, *n*-butylmagnesium chloride, or isopropylmagnesium chloride.

In another embodiment, the C₁₋₈alkylmagnesium halide is *n*-pentylmagnesium chloride and the aprotic organic solvent is THF or 2-MeTHF.

In a further embodiment, a lithium halide is absent.

25

(ii) Alternatively, compound (VII) may be reacted under suitable alkoxycarbonylation conditions, under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; with a base such as DIPEA, K₂CO₃, K₃PO₄, or Cy₂NMe; in a C₁₋₄alcoholic solvent selected from methanol,

ethanol, isopropyl alcohol, *n*-butyl alcohol, or *t*-butyl alcohol; to yield the corresponding compound of formula (1e).

It has been found that a variety of palladium catalysts and phosphorus ligands are suitable for this transformation. In an embodiment, the palladium catalyst is either a pre-formed palladium catalyst or a palladium-ligand catalyst complex that is formed *in situ*.
 When the palladium catalyst is a pre-formed palladium catalyst, it is selected from CAT1 to CAT5, shown in Table 1 (above), and may be used for the preparation of a compound of formula (1e).

In another embodiment, one or more phosphorus ligands selected from L1 to L17, shown in Table 2 (above), may be used in combination with either a pre-formed palladium catalyst (Table 1) or a palladium metal compound (Table 3), for the preparation of a compound of formula (1e).

In another embodiment, a palladium metal compound selected from M1 or M2 (Table 3, above) may be used, in combination with one or more phosphorus ligands selected from L1 to L17 from Table 2, for the above-described alkoxy carbonylation reaction.

Table 4 describes certain reaction conditions (**E1** to **E8**) for the conversion of compound (VII) to methyl ester (1e-1), wherein C₁₋₆alkyl of a compound of formula (1e) is methyl.




Table 4.

Conditions for Alkoxy carbonylation of Compound (VII) to Methyl Ester (1e-1)

	Metal/Cat.	Ligand	Base	Conv. (%)	Yield (%)
E1	Pd(P(<i>t</i> Bu) ₃) ₂	---	DIPEA	100.0	82.1

	Metal/Cat.	Ligand	Base	Conv. (%)	Yield (%)
E2	[Pd(OMs)BA)] ₂	L10	Cy ₂ NMe	99.0	72.5
E3	PdCl ₂ dppf	---	Cy ₂ NMe	98.8	81.7
E4	PdCl ₂ dppf	---	DIPEA	98.7	84.8
E5	[Pd(OMs)BA)] ₂	L17	Cy ₂ NMe	98.4	83.8
E6	[Pd(OMs)BA)] ₂	L13	Cy ₂ NMe	92.0	72.8
E7	Pd(OAc) ₂	L10	Cy ₂ NMe	84.0	75.4
E8	Pd(OAc) ₂	L16	Cy ₂ NMe	78.8	73.0

In an embodiment, the process for the conversion of compound (VII) to a compound of formula (1e) is in the presence of the palladium catalyst Pd(P(*t*Bu)₃)₂ (CAT3, Table 1), and 1.2 equivalents of DIPEA.

5 In another embodiment, the palladium catalyst is comprised, consisting, consisting essentially of the phosphorus ligand L10 (Table 2) and the palladium metal compound [Pd(OMs)(BA)]₂ (M2, Table 3). In another embodiment, the organic base is Cy₂NMe.

In another embodiment, the palladium catalyst is comprised, consisting, or consisting essentially of of the phosphorus ligand dppf (L1, Table 2) and the palladium metal compound palladium acetate (M1, Table 3). In another embodiment, the organic base is Cy₂NMe.

In a further embodiment, the C₁₋₆alcoholic solvent is methanol.

A compound of formula (1e) may be treated with methylamine; in a protic or aprotic solvent such as THF, DMF, DMA, ethanol, or a mixture thereof; at a temperature of about 0 °C to about 60 °C; to yield the corresponding compound (X).

In an embodiment, methylamine is added as a THF solution.

In another embodiment, methylamine is added as a solution in MeOH.

In another embodiment, methylamine is added in its gaseous state.

Direct Conversion of Compound (VII) to Compound (X)

(i) Compound (VII) may be converted directly to compound (X) by reacting compound (VII) in the presence of molybdenum hexacarbonyl; optionally in the presence of one or more reagents such as norbornadiene, tetrabutylammonium bromide, or a base selected from triethylamine or DABCO; in an organic solvent selected from diglyme, dioxane, butyronitrile, propionitrile, or the like; followed by the addition of methylamine; at a temperature of from about 60 °C to about 140 °C; to yield the corresponding compound (X).

In one embodiment, the reagents norbornadiene, tetrabutylammonium bromide, and DABCO are present.

In another embodiment, the organic solvent is butyronitrile or diglyme.


(ii) Alternatively, compound (VII) may be reacted under suitable aminocarbonylation conditions; under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; in the presence of a base selected from DIPEA, K₂CO₃, K₃PO₄, Cy₂NMe, or excess methylamine; in the presence of methylamine; at a temperature of from about room temperature to about 100 °C; to yield the corresponding compound (X).

It has been found that a variety of palladium catalysts and phosphorus ligands are suitable for this transformation. In an embodiment, the palladium catalyst is either a pre-formed palladium catalyst or a palladium-ligand catalyst complex that is formed *in situ*. When the palladium catalyst is a pre-formed palladium catalyst, it is selected from CAT1 to CAT5, shown in Table 1 (above), and may be used for the preparation of compound (X).

In another embodiment, one or more phosphorus ligands selected from L1 to L17, shown in Table 2 (above), may be used in combination with either a pre-formed palladium catalyst (Table 1) or a palladium metal compound (Table 3), for the preparation of compound (X).

In another embodiment, a palladium metal compound selected from M1 or M2 (Table 3, above) may be used, in combination with one or more phosphorus ligands selected from L1 to L17 (Table 2), for the above-described aminocarbonylation reaction.

Table 5 describes certain reaction conditions (**G1** to **G7**) for the conversion of compound (**VII**) to Compound (**X**).



5

Table 5.

Conditions for Aminocarbonylation of Compound (**VII**) to Compound (**X**)

	Metal/Cat. Precursor	Ligand	Base	Conv. [%]	Yield
G1	Pd(P(tBu) ₃) ₂	---	DIPEA	100	95
G2	Pd(OAc) ₂	L10	Cy ₂ NMe	100	93.9
G3	Pd(OAc) ₂	L16	Cy ₂ NMe	100	93.1
G4	[Pd(OMs)BA] ₂	L10	Cy ₂ NMe	100	91.8
G5	[Pd(OMs)BA] ₂	L16	Cy ₂ NMe	100	88.5
G6	Pd(OAc) ₂	L16	K ₃ PO ₄	100	83.7
G7	Pd(OAc) ₂	L17	Cy ₂ NMe	95.1	83.5

In one embodiment, the palladium catalyst is Pd(P(tBu)₃)₂ (CAT3, Table 1), and the organic base is 1.2 equivalents of DIPEA.

10 In another embodiment, the palladium catalyst is comprised, consisting or consisting essentially of the phosphorus ligand L10 (Table 2) and the palladium metal compound Pd(OAc)₂ (M1, Table 3). In a further embodiment, the base is Cy₂NMe.

In one embodiment, methylamine is added as a solution in a protic or aprotic solvent.

15 In another embodiment, methylamine is added as a THF solution.

In another embodiment, methylamine is added in its gaseous state.

In another embodiment, methylamine is added as a solution in methanol.

In yet another embodiment, methylamine is added as its methyl ammonium hydrochloride salt.

In another embodiment, the organic solvent is THF.


One skilled in the art will further recognize that the reaction or process step(s) as herein described (or claimed) are allowed to proceed for a sufficient period of time, at a
5 suitable temperature or range of temperatures, until the reaction is complete, as determined by any method known to one skilled in the art, for example, chromatography (e.g. HPLC, TLC, etc.). In this context a “completed reaction or process step” means that the reaction mixture contains a decreased amount of the starting material(s) / reagent(s) and an
10 increased amount of the desired product(s), as compared to the amounts of each present at the beginning of the reaction.

Specific Examples

The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth
15 in the claims which follow thereafter.

In the Examples that follow, some synthesis products are listed as having been isolated as a residue. It will be understood by one of ordinary skill in the art that the term “residue” does not limit the physical state in which the product was isolated and may
20 include, for example, a solid, an oil, a foam, a gum, a syrup, and the like.

Example 1




5 Step A. Preparation of Compound II.



A vessel was charged with 19 g of compound (I), 5 g of triethylamine
 10 hydrobromide, 49 g of xylenes and 67 g DMF. A solution of 26 g of phosphorous
 oxybromide in 16 g of xylene was dosed into the reaction mixture. The reaction mixture
 was heated to 100 °C for 3 h. The mixture was then cooled to 70 °C. To this mixture was
 added 75 g of a solution of NaOH (10M). After phase separation at room temperature, the

organic layer was washed with a 84 g of an aqueous solution of NaOH (10M) followed by 84 g of an aqueous solution of NaCl (25 %). The organic phase was carried forward into the next step without further purification. Isolation by crystallization from heptane was performed for characterization purposes of compound (II). ¹H NMR (300 MHz, CDCl₃) δ 9.36, 8.75.

Step B. Preparation of Compound (III).



To the previous solution of compound (II) in xylenes was added 8.7 g of sodium cyanide and 6.8 g of copper (I) iodide and 45 g of butyronitrile. The mixture was heated to 120 °C for 20 h. The reaction mixture was cooled, washed twice with an aqueous solution of sodium carbonate (10%). The organic phase was carried forward into the next step. Isolation was performed for characterization purposes of compound (III). ¹H NMR (300 MHz, DMSO-*d*₆) δ 149.3, 145.4, 133.9, 131.9, 130.1, 119.5, 114.0.

Step C. Preparation of Compound (IV).

Preparation of modified catalyst slurry.

In a 20 mL beaker glass 0.156 g (0.129 mL, 50 % w/w) of H₃PO₂ was added to a slurry of 1.00 g 5 % Pt/C catalyst F101 R/W (from Evonik AG, contains ~60 % water) and 4.0 mL of deionized water. After 15 minutes while stirring with a magnetic stirring bar, 58 mg of NH₄VO₃ was added and the slurry was again stirred for 15 minutes.


Hydrogenation.

A 100 mL autoclave was charged with a solution of 10.0 g of compound (III) (46.1 mmol) in 26.7 mL of xylenes and 13.3 mL of butyronitrile. To this solution, the modified catalyst slurry was added with the aid of 2 mL of deionized water. The autoclave was closed, then inertized by pressurizing 3 times with nitrogen to 10 bar and 3 times hydrogen to 10 bar. The reactor pressure was set to 5.0 bar hydrogen, stirring was started (hollow

shaft turbine stirrer, 1200 rpm) and the mixture heated up to 70 °C within 50 min. As soon as 70 °C was reached, the hydrogen uptake ceased. After stirring for another 40 min, the heating was stopped and the autoclave was allowed to cooling. The slurry was filtered through a fiberglass filter and washed in portions using 40 mL of xylenes at 20-23 °C.

- 5 Compound (IV) was crystallized from the solution upon distillation of the butyronitrile solvent. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.20 (d, J=2.4Hz, 1H), 7.31 (d, J=2.6Hz, 1H), 7.04 (s, NH).

Step D. Preparation of Compound (VII).




10

To a reactor containing compound (VI) (25 g) and compound (IV) (14 g) was added 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one (18 g) and toluene (316 mL). The reaction mixture was stirred and heated to 100 °C for 20 h. A solvent switch from toluene to DMA (8 L/kg final composition) was performed, then EtOH (400 mL) was added. The mixture was then heated to 70 °C before addition of HCl (2 M, 160 mL). After stirring for 2 h, the reaction was cooled down to 0 °C. The precipitate was collected by filtration, rinsed with EtOH/H₂O (100 mL, 1:1), and dried to give compound (VII) (24 g, 63%). ¹H NMR (300 MHz, CDCl₃) δ 9.09 (d, J=2.1Hz, 1H), 8.35 (d, J=2.1Hz, 1H), 8.01 (dd, J=8.3, 6.8Hz, 1H), 7.07 (dd, J=7.9, 2.3Hz, 1H), 6.94 (dd, JJ=8.0, 2.0Hz, 1H), 2.72 (m, 2H), 2.58 (m, 2H), 2.30 (m, 1H), 1.74 (m, 1H).

15

20


Step E. Preparation of Compound (VIII).



VIII

A reactor was charged with a solution of 5 g of compound (VII) in 50 mL of anhydrous THF and stirring begun. The reaction solution was cooled to an internal
5 temperature of 0 °C. A solution of *n*-pentylmagnesium chloride (1 eq) was added slowly to maintain a reaction temperature of 0 °C. After 30 min, carbon dioxide gas was added into the stirred reaction mixture. Upon consumption of the starting material, the reaction mixture was added to a solution of aqueous acetic acid (10 %) to yield compound (VIII) (75 %). ¹H NMR (300 MHz, CDCl₃) δ 9.11 (d, 1H), 8.37 (d, 1H), 8.20 (m, 1H), 7.25 (m,
10 2H), 5.30 (s, 1H), 2.75 (m, 2H), 2.61 (m, 2H), 2.31 (m, 1H), 1.74 (m, 1H).

Step F. Preparation of Compound (IX).



IX


Method A. A pressure reactor was charged with Compound (VII) (1 g), palladium acetate (10 mol%), dppf (10 mol%), and diisopropylamine (1 eq) and methanol (10 mL).
15 The reaction was placed under carbon monoxide (4 bar) and heated for 4 h at 60 °C. The reaction was allowed to cool to ambient temperature, diluted with dichloromethane (5 mL), then washed with a 3% cysteine aqueous solution. The organic layer was separated, concentrated, and dried to yield compound (IX) (85 %). ¹H NMR (300 MHz, CDCl₃) δ
20 9.10 (d, *J* = 1.9 Hz, 1H), 8.36 (d, *J* = 1.9 Hz, 1H), 8.20 (m, 1H), 7.20 (m, 2H), 4.00 (s, 3H),

2.75 (m, 2H), 2.58 (m, 2H), 2.30 (m, 1H), 1.76 (m, 1H); ^{13}C NMR (CDCl_3 , JMOD) δ 179.6, 174.2, 163.3, 159.2, 153.4 (ArH), 140.9, 135.5 (ArH), 132.9 (ArH), 128.9, 126.5 (ArH), 118.9(ArH), 114.2, 67.7, 52.6, 31.1, 13.4.

Method B. A reactor was charged with 2.5 g of compound (VII) in 25 mL 2-methyl-THF. The mixture was stirred under Argon at -15°C . A solution of *n*-pentylmagnesium chloride in THF (2M, 2.4 mL) was dosed over 1 h. After 15 min of stirring, methyl chloroformate (1.1 eq, 0.40 mL) was added dropwise and the temperature was then allowed to warm to 15°C . The reaction was quenched with a solution of 10% AcOH in water (20 mL). After phase separation, the organic layer was washed with water and then concentrated to yield compound (IX) in 77 % yield.

Method C. A reactor was charged with 2 g of compound (VII) in 20 mL of THF. The mixture was stirred under Argon at 50°C . A solution of isopropylmagnesium chloride lithium chloride complex in THF (1.3M, 3.4 mL) was dosed over 10 min. After 5 min of stirring, methyl cyanoformate (1.25 eq, 0.37 mL) was added dropwise and the temperature was then allow to warm to 15°C . The reaction was quenched with a solution of 10% AcOH in water (20 mL). After the phase separation, the organic layer was washed with water and then concentrated to yield compound (IX) in 75% yield.


Step G. Preparation of Compound (X).



A reactor was charged with compound (IX) (0.3 g) and a solution of methylamine in ethanol (10 eq) and stirring begun. The reaction was stirred at ambient temperature. Upon consumption of compound (IX), the reaction was concentrated, re-dissolved in toluene, and washed with aqueous HCl (2M) until all base was neutralized. The toluene phase was then concentrated to give compound (X) (80 %). ^1H NMR (300 MHz, DMSO) δ 9.22 (d, $J = 1.9$ Hz, 1H), 8.76 (d, $J = 1.9$ Hz, 1H), 8.50 (d, $J = 4.5$ Hz, 1H), 7.84 (t, J

=2x8.0Hz, 1H), 7.48 (dd, J =10.5, 1.8Hz, 1H), 7.39 (dd, J =8.2, 1.8Hz, 1H), 4.00 (s, 3H), 2.75 (m, 2H), 2.58 (m, 2H), 2.30 (m, 1H), 1.76 (m, 1H).

Example 2



5

Method A. In a 10 mL test tube, compound (VII) (0.3 g, 0.55 mmol), molybdenum hexacarbonyl (0.145 g, 0.55 mmol), norbornadiene (0.05 g, 0.545 mmol), tetrabutylammonium bromide (0.177 g, 0.55 mmol) and DABCO (0.185 g, 1.65 mmol) were charged under nitrogen, followed by 3 mL of diglyme. The mixture was heated with stirring under a nitrogen atmosphere to 140 °C. Methylamine hydrochloride (0.05 g, 0.61 mmol) was added, and the mixture was stirred at 140 °C for 1 h to yield compound (X) (13 %).

Method B. In a 10 mL test tube, compound (VII) (0.3 g, 0.55 mmol), molybdenum hexacarbonyl (0.145 g, 0.55 mmol), norbornadiene (0.05 g, 0.545 mmol), tetrabutylammonium bromide (0.177 g, 0.55 mmol) and DABCO (0.185 g, 1.65 mmol) were charged under nitrogen, followed by 3 mL of butyronitrile. The mixture was heated with stirring under a nitrogen atmosphere to 140 °C. Methylamine hydrochloride (0.05 g, 0.61 mmol) was added in 3 portions over 30 min, and the mixture was stirred at 118 °C for 1 h to yield compound (X) (43 %).

Method C. A 30 mg (0.059 mmol) portion of Pd(*t*-Bu₃P)₂ was placed in a 10 mL Schlenk flask, which was subsequently set under an inert atmosphere (Argon). Then 3 mL of degassed THF was added and the solution stirred for 5 min at ambient temperature. In a second 20 mL Schlenk flask, 0.8 g of compound (VII) (1.464 mmol) was inertized and 4.3 mL degassed THF, 3.7 mL (7.32 mmol, 2M in THF) N-methylamine, and 0.37 mL dicyclohexylmethylamine (1.75 mmol) were added. Both the substrate solution and the catalyst solution were transferred via cannula into the 50 mL autoclave, which was

25


previously set under an inert atmosphere of Argon. The reactor was sealed and purged with Argon, and finally the Argon was replaced by 5 bar CO (three purge cycles). The reaction was stirred and heated to 60 °C for 2 h.

- 5 While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.


CLAIMS

What is claimed is:


1. A process for the preparation of compound (X)




comprising



reacting compound (V) with cyclobutanone in the presence of sodium cyanide; in acetic acid, or a solvent system comprised of an alcoholic solvent and a protic acid; at a temperature of about 0 °C to about 20 °C; to yield the corresponding compound (VI);




reacting compound (IV) and compound (VI) in the presence of a thiocarbonylating agent; in an organic solvent; at a temperature of about 0 °C to about 100 °C; to yield the corresponding compound (VII);




converting compound (VII) to compound (X).

2. The process of claim 1, wherein step (1a) further comprises




reacting compound (V) with cyclobutanone in the presence of at least one molar equivalent of sodium cyanide; in acetic acid, or a solvent system comprised of at least one molar equivalent of acetic acid or hydrochloric acid and a C₁₋₄alcoholic solvent selected from the group consisting of methanol, ethanol, propanol, and butanol; at a temperature of about 0 °C to about 20 °C; to yield the corresponding compound (VI).

3. The process of claim 2 wherein the solvent system is acetic acid.
4. The process of claim 2 wherein the solvent system is 90% acetic acid and 10% ethanol.
5. The process of claim 1, wherein step (1b) further comprises



reacting compound (IV) and compound (VI) in the presence of a thiocarbonylating agent selected from the group consisting of 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one, 1,1'-thiocarbonyl diimidazole, phenylthionochloroformate, beta-naphthyl thionochloroformate, 1,1'-thiocarbonylbis(pyridin-2(1*H*)-one), *O,O*-di(pyridin-2-yl)carbonothioate, 1,1'-thiocarbonylbis (1*H*-benzotriazole), and thiophosgene; in an organic solvent selected from the group consisting of THF, 2-methyl-THF, acetonitrile, DMA, toluene, DMF, NMP, and DMSO; at a temperature of about 0 °C to about 100 °C; to yield the corresponding compound (VII).

6. The process of claim 5 wherein the thiocarbonylating agent is 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one.
7. The process of claim 6 wherein the organic solvent is DMA.
8. The process of claim 1, wherein step (1x) further comprises the conversion of compound (VII) to compound (X) via carboxylic acid (1c), by




reacting compound (VII) with an organomagnesium halide; in the presence or absence of a lithium halide; followed by the addition of carbon dioxide gas; in an aprotic organic solvent; at a temperature of about 0 °C; to yield the corresponding carboxylic acid compound (1c).

9. The process of claim 8, comprising reacting compound (VII) with an organomagnesium halide selected from the group consisting of a C₁₋₈alkylmagnesium halide and a C₅₋₇cycloalkylmagnesium halide; in the presence or


absence of a lithium halide selected from the group consisting of lithium chloride, lithium bromide, and lithium iodide; followed by the addition of carbon dioxide gas; in an aprotic organic solvent selected from the group consisting of THF, 2-MeTHF, MTBE, CPME, and toluene; at a temperature of about 0 °C; to yield the corresponding carboxylic acid compound (1c).

10. The process of claim 9 wherein the C₁₋₈alkylmagnesium halide is a C₁₋₈alkylmagnesium chloride or C₁₋₈alkylmagnesium bromide.
11. The process of claim 10 wherein the C₁₋₈alkylmagnesium halide is selected from the group consisting of isopropylmagnesium chloride, *sec*-butylmagnesium chloride, *n*-pentylmagnesium chloride, hexylmagnesium chloride, ethylmagnesium chloride, ethylmagnesium bromide, *n*-butylmagnesium chloride, and isopropylmagnesium chloride.
12. The process of claim 11 further comprising reacting compound (VII) with *n*-pentylmagnesium chloride; in the absence of a lithium halide; followed by the addition of carbon dioxide gas; in THF; at a temperature of about 0 °C; to yield the corresponding carboxylic acid compound (1c).
13. The process of claim 9 wherein the C₅₋₇cycloalkylmagnesium halide is a C₅₋₇cycloalkylmagnesium chloride or C₅₋₇cycloalkylmagnesium bromide.
14. The process of claim 13 wherein the C₅₋₇cycloalkylmagnesium halide is cyclohexylmagnesium chloride.
15. The process of claim 1, wherein step (1x) further comprises the conversion of compound (VII) to compound (X) via carboxylic acid (1c), by



reacting compound (VII) under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; with an organic base; in the presence of water; in an organic solvent; at a temperature of about 0 °C to about 100 °C; to yield the corresponding compound (1c).


16. The process of claim 15 wherein the palladium catalyst is comprised of a phosphorus ligand that is dppf and a palladium metal compound that is palladium acetate.
17. The process of claim 1 wherein step (1x) further comprises the conversion of compound (1c) to compound (X) via carboxylic acid (1c), by



reacting compound (1c) with a coupling agent; in an aprotic or protic solvent; at about room temperature; followed by the addition of methylamine; to yield the corresponding compound (X).

18. The process of claim 17, further comprising reacting compound (1c) with a coupling agent that is CDI; wherein the aprotic or protic solvent is THF or toluene; at about room temperature; followed by the addition of methylamine; to yield the corresponding compound (X).


19. The process of claim 18 wherein methylamine is added as a THF solution.
20. The process of claim 18 wherein methylamine is added in its gaseous state.
21. The process of claim 18 wherein methylamine is added as its methyl ammonium salt.
22. The process of claim 1, wherein step (1x) further comprises the conversion of compound (VII) to compound (X) via an ester of formula (1e), by



reacting compound (VII) with an organomagnesium halide; in the presence or absence of a lithium halide; in an aprotic organic solvent; at a temperature of about -50 °C to about room temperature; followed by the addition of an C₁₋₆alkyl chloroformate or C₁₋₆alkyl cyanoformate; to yield the corresponding ester of formula (1e).

23. The process of claim 22, wherein step (1e) further comprises reacting compound (VII) with an organomagnesium halide selected from the group consisting of a C₁₋₈alkylmagnesium halide and a C₅₋₇cycloalkylmagnesium halide; in the presence or absence of a lithium halide selected from the group consisting of lithium chloride, lithium bromide, and lithium iodide; in an aprotic organic solvent selected from THF, 2-MeTHF, or toluene; at a temperature of about -50 °C to about 22 °C; followed by the addition of an C₁₋₆alkyl chloroformate or C₁₋₆alkyl cyanoformate; to yield the corresponding ester of formula (1e).


24. The process of claim 23 wherein the C₁₋₈alkylmagnesium halide is a C₁₋₈alkylmagnesium chloride or C₁₋₈alkylmagnesium bromide.
25. The process of claim 24 wherein the C₁₋₈alkylmagnesium halide is selected from the group consisting of isopropylmagnesium chloride, *sec*-butylmagnesium chloride, cyclohexylmagnesium chloride, *n*-pentylmagnesium chloride, hexylmagnesium chloride, ethylmagnesium chloride, ethylmagnesium bromide, *n*-butylmagnesium chloride, and isopropylmagnesium chloride.
26. The process of claim 25 further comprising reacting compound (VII) in the presence of *n*-pentylmagnesium chloride; in the absence of a lithium halide; in an aprotic organic that is THF or 2-MeTHF; at a temperature of about -50 °C to about 22 °C; followed by the addition of an C₁₋₆alkyl chloroformate or C₁₋₆alkyl cyanoformate; to yield the corresponding ester of formula (1e).
27. The process of claim 23 wherein the C₅₋₇cycloalkylmagnesium halide is a C₅₋₇cycloalkylmagnesium chloride or C₅₋₇cycloalkylmagnesium bromide.
28. The process of claim 27 wherein the C₅₋₇cycloalkylmagnesium halide is cyclohexylmagnesium chloride.
29. The process of claim 1, wherein step (1x) further comprises the conversion of compound (VII) to compound (X) via an ester of formula (1e), by



reacting compound (VII) under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus


ligands; with a base; in a C₁₋₆alcoholic solvent; at a temperature of about room temperature to about 100 °C; to yield the corresponding ester of formula (1e).

30. The process of claim 29, wherein step (1e) further comprises reacting compound (VII) under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; in the presence of a base selected from the group consisting of DIPEA, K₂CO₃, K₃PO₄, and Cy₂NMe; in a C₁₋₄alcoholic solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol, *n*-butyl alcohol, and *t*-butyl alcohol; at a temperature of about room temperature to about 100 °C; to yield the corresponding ester of formula (1e).
31. The process of claim 30 wherein the palladium catalyst is Pd(P(*t*Bu)₃)₂ and the base is 1.2 equivalents of DIPEA.
32. The process of claim 30, wherein the palladium catalyst is comprised of a phosphorus ligand, L10, and a palladium metal compound that is [Pd(OMs)(BA)]₂; in the presence of Cy₂NMe.




33. The process of claim 30 wherein the palladium catalyst is comprised of a phosphorus ligand, dppf, and a palladium metal compound that is palladium acetate; in the presence of DIPEA.
34. The process of claim 28 wherein the C₁₋₄alcoholic solvent is methanol.

35. The process of claim 1, wherein step (1x) further comprises the conversion of the ester of formula (1e) to compound (X), by



treating an ester of formula (1e) with methylamine; in a protic or aprotic solvent; at a temperature of about 0 °C to about 60 °C; to yield the corresponding compound (X).


36. The process of claim 35 wherein the protic or aprotic solvent is selected from the group consisting of THF, DMF, DMA, and ethanol, or a mixture thereof.
37. The process of claim 36 wherein the methylamine is added as a THF solution.
38. The process of claim 36 wherein the methylamine is added as a MeOH solution.
39. The process of claim 36 wherein the methylamine is added in its gaseous state.
40. The process of claim 1 wherein step (1x) further comprises the conversion of compound (VII) directly to compound (X), by



reacting compound (VII) in the presence of molybdenum hexacarbonyl; optionally in the presence of one or more reagents selected from the group

consisting of norbornadiene, tetrabutylammonium bromide, and a base selected from triethylamine or DABCO; in an organic solvent selected from the group consisting of diglyme, dioxane, butyronitrile, and propionitrile; followed by the addition of methylamine; at a temperature of about 60 °C to about 140 °C; to yield the corresponding compound (X).

41. The process as in claim 40 wherein norbornadiene, tetrabutylammonium bromide, and DABCO are present.
42. The process as in claim 41 wherein the organic solvent is butyronitrile or diglyme.
43. The process as in claim 1, wherein step (1x) further comprises the conversion of compound (VII) directly to compound (X), by




reacting compound (VII) under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; in the presence of a base; in the presence of methylamine; in an organic solvent; at a temperature of about room temperature to about 100 °C; to yield the corresponding compound (X).

44. The process as in claim 43 wherein step (1g) further comprises reacting compound (VII) under a carbon monoxide atmosphere; in the presence of a palladium catalyst; in the presence of one or more phosphorus ligands; in the presence of a base selected from the group consisting of DIPEA, K₂CO₃, K₃PO₄, Cy₂NMe, and excess methylamine; in the presence of methylamine; in an organic solvent; at a

temperature of about room temperature to about 100 °C; to yield the corresponding compound (X).

45. The process as in claim 44 wherein the palladium catalyst is $\text{Pd}(\text{P}(\text{tBu}_3)_2)$ and the base is DIPEA.
46. The process as in claim 44 wherein the palladium catalyst is comprised of the phosphorus ligand, L10, and the palladium metal compound $\text{Pd}(\text{OAc})_2$; in the presence of Cy_2NMe .



47. The process as in claim 44 wherein methylamine is added as a THF solution .
48. The process as in claim 44 wherein methylamine is added as a MeOH solution.
49. The process as in claim 44 wherein methylamine is added in its gaseous state.
50. The process as in claim 44 wherein methylamine is added as its methyl ammonium hydrochloride salt.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/066345A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D401/04
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2007/126765 A2 (UNIV CALIFORNIA [US]; JUNG MICHAEL E [US]; SAWYERS CHARLES L [US]; OUK) 8 November 2007 (2007-11-08) page 19; compound A52 -----	1-50
A	WO 2008/119015 A2 (SLOAN KETTERING INST CANCER [US]; OVERFELLI OUATHEK [US]; DILHAS ANNA) 2 October 2008 (2008-10-02) page 54; compound A52 -----	1-50
A	WO 2011/103202 A2 (ARAGON PHARMACEUTICALS INC [US]; SMITH NICHOLAS D [US]; BONNEFOUS CELI) 25 August 2011 (2011-08-25) examples 4,34; compounds 231,224 -----	1-50



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 March 2016

Date of mailing of the international search report

31/03/2016

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Johnson, Claire

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2015/066345

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007126765	A2	08-11-2007	
		AU 2007243651 A1	08-11-2007
		BR PI0709771 A2	26-07-2011
		CN 101454002 A	10-06-2009
		DK 2368550 T3	30-09-2013
		EP 2004181 A2	24-12-2008
		EP 2368550 A1	28-09-2011
		EP 2656841 A1	30-10-2013
		EP 2656842 A2	30-10-2013
		ES 2428291 T3	06-11-2013
		HK 1163495 A1	21-02-2014
		JP 5133975 B2	30-01-2013
		JP 2009531439 A	03-09-2009
		JP 2012092149 A	17-05-2012
		JP 2014133755 A	24-07-2014
		JP 2016011315 A	21-01-2016
		JP 2016014069 A	28-01-2016
		NZ 572335 A	30-09-2011
		PT 2368550 E	03-12-2013
		US 2011003839 A1	06-01-2011
		US 2013072511 A1	21-03-2013
		US 2014309262 A1	16-10-2014
		WO 2007126765 A2	08-11-2007
WO 2008119015	A2	02-10-2008	
		US 2010190991 A1	29-07-2010
		US 2013225821 A1	29-08-2013
		US 2015191449 A1	09-07-2015
		WO 2008119015 A2	02-10-2008
WO 2011103202	A2	25-08-2011	
		AU 2011218173 A1	26-07-2012
		CA 2787083 A1	25-08-2011
		CN 102884057 A	16-01-2013
		CN 103724322 A	16-04-2014
		EA 201270720 A1	29-03-2013
		EA 201590590 A1	30-11-2015
		EP 2536708 A2	26-12-2012
		EP 2824102 A1	14-01-2015
		HK 1206018 A1	31-12-2015
		JP 2013519733 A	30-05-2013
		KR 20120135250 A	12-12-2012
		SG 183302 A1	27-09-2012
		SG 10201501202T A	29-04-2015
		US 2013116258 A1	09-05-2013
		US 2015182529 A1	02-07-2015
		WO 2011103202 A2	25-08-2011